Onkolojik Tedaviye Bağlı Pulmoner Hipertansiyonda Tanı ve Tedavi Yaklaşımları

Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33(2):325-331.Doi: 10.1183/09031936.00087608

Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119 Doi: 10.1093/eurheartj/ehv317.

Sun XG, Hansen JE, Oudiz RJ, et al. Pulmonary function in primary pulmonaryhypertension. J Am Coll Cardiol 2003;41(6):1028-1035.Doi: 10.1016/s0735-1097(02)02964-9

Tunariu N, Gibbs SJR, Win Z, et al.Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007;48(5):680-684.Doi: 10.2967/jnumed.106.039438

Rajaram S, Swift AJ, Condliffe R, et al.CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax 2015;70(4):382-387.Doi: 10.1136/thoraxjnl-2014-206088

Peacock AJ, Vonk Noordegraaf A. Cardiac magnetic resonance imaging in pulmonary arterial hypertension. Eur Respir Rev 2013;22(130):526-534.Doi: 10.1183/09059180.00006313

Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur

Respir J 2008;32:503 –512.

Simonneau G,Montani D, Celermajer D.S, et al.Haemodynamic definitions and updated clinical classification of pulmonary hypertensionEuropean Respiratory Journal 2019;53(1): 1801913.Doi: 10.1183/13993003.01913-2018

Savarese G, Paolillo S, Costanzo P, et al.Do changes of 6-minute walk distancepredict clinical events in patients with pulmonary arterial hypertension?: a meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012;60(13):1192-1201.Doi: 10.1016/j.jacc.2012.01.083

1Montani D, Achouh L, Dorfmüller P, et al.Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore). 2008;87(4):220-233.doi: 10.1097/MD.0b013e31818193bb

Kramer MR, Estenne M, Berkman N, et al. Radiation-induced pulmonary venoocclusive disease. Chest. 1993;104(4):1282-1284.Doi: 10.1378/chest.104.4.1282

Salzman D, Adkins DR, Craig F, et al. Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant. 1996;18(4):755–760.

Ballout FA, Manshad AS, Okwuosa TM.Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and ManagementCurrent Treatment Options in Cardiovascular Medicine 2017;19(6):44.Doi: 10.1007/s11936-017-0543-5

Galiè N, Channick RN, FrantzRP,et al.Risk stratification and medical therapy of pulmonary arterial hypertensionEuropean Respiratory Journal 2019;53(1):1801889. Doi: 10.1183/13993003.01889-2018

Condon DF, Nickel NP, Anderson R, et al.The 6th World Symposium on Pulmonary Hypertension: what’s old is new.F1000Res. 2019;19;8:F1000 Faculty Rev-888. Doi:10.12688/f1000research.18811.1

Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060-1064. Doi:10.1002/ajh.24174

Jaïs X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012;40(4):881-885.Doi:10.1183/09031936.00141211

de Man FS, Handoko ML, Groepenhoff H,et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34(3):669–675.Doi: 10.1183/09031936.00027909

Meyer S, McLaughlin VV, Seyfarth HJ, et al.Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013;41(6):1302-1307. Doi:10.1183/09031936.00089212

Ruiter G, Lankhorst S, Boonstra A,et al.Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011;37(6):1386-1391.Doi: 10.1183/09031936.00100510

Galie´ N, Olschewski H, Oudiz RJ, et al.Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-3019.Doi: 10.1161/CIRCULATIONAHA.107.74251

Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-1123.Doi: 10.1016/S0140-6736(01)06250-X

Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809 –818.Doi: 10.1056/NEJMoa1213917

Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44(7):1488–1496.Doi: 10.1016/j.jacc.2004.06.060

Singh T, Rohit M, Grover A,et al. A randomized, placebocontrolled,double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151(4):851.e1-5.Doi: 10.1016/j.ahj.2005.09.006

Galie` N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-2903.Doi: 10.1161/CIRCULATIONAHA.108.839274

Ghofrani HA, Galie` N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369(4):330-340.Doi: 10.1056/NEJMoa1209655

Galie` N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003;2(2):123-137.Doi: 10.1007/BF03256644

Sitbon O, Delcroix M, Bergot E,et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am Heart J 2014;167(2):210-217.Doi: 10.1016/j.ahj.2013.08.007.

Simonneau G, Barst RJ, Galie` N,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-804. Doi: 10.1164/ajrccm.165.6.2106079

Sitbon O, Channick R, Kelly C, et al.. Selexipag for the Treatment of Pulmonary Arterial Hypertension. New Engl J Med 2015;373(26):2522-2533. Doi: 10.1056/NEJMoa1503184

Kurzyna M, Dabrowski M, Bielecki D,et al. Atrial septostomy in treatment of end-stage right heart failure in Patients with pulmonary hypertension. Chest 2007;131(4):977-983.Doi: 10.1378/chest.06-1227

Toyoda Y, Thacker J, Santos R, et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann Thorac Surg 2008;86(4):1116-1122.Doi: 10.1016/j.athoracsur.2008.05.049

Sinan ÜY, MeriçM, Özen DK.6. Dünya Pulmoner Hipertansiyon Sempozyumu (6. WSPH)PH Gündem 2018;2.

Montani D, Price LC, Dorfmuller P,et al. Pulmonary veno-occlusive disease. Eur Respir J 2009 33(1):189-200.Doi: 10.1183/09031936.00090608

Montani D, Jaı¨s X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009;34(6):1348-1356.Doi: 10.1183/09031936.00017809.